Bioinformatics Analysis of Programmed Death-1Trastuzumab Resistance Regulatory Networks in Breast Cancer Cells

Hermawan, Adam and Putri, Herwandhani (2025) Bioinformatics Analysis of Programmed Death-1Trastuzumab Resistance Regulatory Networks in Breast Cancer Cells. Asian Pacific Journal of Cancer Prevention, 26 (1). 279 - 292. ISSN 15137368

[thumbnail of APJCP_Volume 26_Issue 1_Pages 279-292.pdf] Text
APJCP_Volume 26_Issue 1_Pages 279-292.pdf - Published Version
Restricted to Registered users only

Download (8MB) | Request a copy

Abstract

Objective: Programmed cell death-1 (PD-1, encoded by PDCD1) regulatory network participates in glioblastoma multiforme development. However, such a network in trastuzumab-resistant human epidermal growth factor receptor 2-positive (HER2+) breast cancer remains to be determined. Accordingly, this study was aimed to explore the PD-1 regulatory network responsible for the resistance of breast cancer cells to trastuzumab through a bioinformatics approach. Methods: The study used data mining tools like cBioportal and OMIM to identify genes involved in the programmed cell death-1trastuzumab resistance regulatory network. The network was further examined using various tools like WebGestalt, DAVID, STRING, Cytoscape, CytoHubba, GEPIA, TNMPlot, and ROCPlot. Results: The PDCD1 regulatory network in trastuzumab-resistant HER2+ breast cancer is linked to Cytotoxic T-lymphocyte associated antigen 4 (CTLA-4), interleukin (IL)-10, protein tyrosine phosphatase receptor type C (PTPRC), and FCGR2B. These factors have a significant prognostic power in pathological complete response in breast cancer patients treated with trastuzumab. Infiltration of B cells, CD8+ cells, CD4+ cells, neutrophils, dendritic cells, macrophages, and regulatory T cells is directly correlated with PTR expression. Conclusion: The study identified four genes (CTLA4, IL10, PTPRC, and FCGR2B) that are linked to the regulatory network of PD-1 in trastuzumab-resistant HER2+ breast cancer cells. Further research is needed to develop the therapeutic target against trastuzumab resistance in HER2+ breast cancer. © (2025), (Asian Pacific Organization for Cancer Prevention). All rights reserved.

Item Type: Article
Additional Information: Cited by: 2; All Open Access; Gold Open Access; Green Open Access
Uncontrolled Keywords: Antineoplastic Agents, Immunological; Biomarkers, Tumor; Breast Neoplasms; Computational Biology; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Prognosis; Programmed Cell Death 1 Receptor; Receptor, ErbB-2; Trastuzumab; epidermal growth factor receptor 2; ERBB2 protein, human; immunological antineoplastic agent; PDCD1 protein, human; programmed death 1 receptor; trastuzumab; tumor marker; bioinformatics; breast tumor; drug resistance; drug therapy; female; gene expression regulation; gene regulatory network; genetics; human; metabolism; pathology; procedures; prognosis
Subjects: R Medicine > RM Therapeutics. Pharmacology
R Medicine > RS Pharmacy and materia medica
Divisions: Faculty of Pharmacy
Depositing User: Muh Aly Mubarok
Date Deposited: 16 Nov 2026 07:42
Last Modified: 16 Nov 2026 07:42
URI: https://ir.lib.ugm.ac.id/id/eprint/30236

Actions (login required)

View Item
View Item